{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:15:16Z","timestamp":1789085716663,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01511-0","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:02:33Z","timestamp":1738760553000},"page":"191-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical features, diagnosis, and treatment of pembrolizumab induced autoimmune encephalitis"],"prefix":"10.1007","volume":"43","author":[{"given":"Li","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"4","key":"1511_CR1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"37","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF (2015) The Next Immune-Checkpoint inhibitors: PD-1\/PD-L1 blockade in Melanoma. Clin Ther 37(4):764\u2013782. https:\/\/doi.org\/10.1016\/j.clinthera.2015.02.018","journal-title":"Clin Ther"},{"issue":"1","key":"1511_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/JCO.18.00145","volume":"37","author":"AM Tsimberidou","year":"2019","unstructured":"Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM et al (2019) Trial reporting in Immuno-Oncology (TRIO): an American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol 37(1):72\u201380. https:\/\/doi.org\/10.1200\/JCO.18.00145","journal-title":"J Clin Oncol"},{"issue":"11","key":"1511_CR3","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777\u20132789. https:\/\/doi.org\/10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1511_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1511_CR5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2174\/1570159X19666201230151224","volume":"19","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Zhang C, Zhou L, Dong P, Shi L (2021) Immune Checkpoint inhibitors and neurotoxicity. Curr Neuropharmacol 19(8):1246\u20131263. https:\/\/doi.org\/10.2174\/1570159X19666201230151224","journal-title":"Curr Neuropharmacol"},{"key":"1511_CR6","doi-asserted-by":"publisher","first-page":"117955492110562","DOI":"10.1177\/11795549211056261","volume":"15","author":"K Cheng","year":"2021","unstructured":"Cheng K, Wang Y, Zhou Y, Xia R, Tang L, Liu J (2021) Neurological adverse events Induced by Immune checkpoint inhibitors in Non-small Cell Lung Cancer: current perspectives and New Development. Clin Med Insights Oncol 15:11795549211056261. https:\/\/doi.org\/10.1177\/11795549211056261","journal-title":"Clin Med Insights Oncol"},{"issue":"3","key":"1511_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","volume":"24","author":"M Xu","year":"2019","unstructured":"Xu M, Nie Y, Yang Y, Lu YT, Su Q (2019) Risk of neurological toxicities following the use of different Immune checkpoint inhibitor regimens in solid tumors: a systematic review and Meta-analysis. Neurologist 24(3):75\u201383. https:\/\/doi.org\/10.1097\/NRL.0000000000000230","journal-title":"Neurologist"},{"issue":"1","key":"1511_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","volume":"7","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H et al (2019) Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 7(1):106. https:\/\/doi.org\/10.1186\/s40425-019-0585-1","journal-title":"J Immunother Cancer"},{"issue":"36","key":"1511_CR9","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"1","key":"1511_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"1511_CR11","doi-asserted-by":"publisher","first-page":"804597","DOI":"10.3389\/fimmu.2022.804597","volume":"13","author":"R Poto","year":"2022","unstructured":"Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG et al (2022) Holistic Approach to Immune Checkpoint inhibitor-related adverse events. Front Immunol 13:804597. https:\/\/doi.org\/10.3389\/fimmu.2022.804597","journal-title":"Front Immunol"},{"issue":"2","key":"1511_CR12","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1212\/NXI.0000000000000663","volume":"7","author":"T Cellucci","year":"2020","unstructured":"Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS et al (2020) Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm 7(2):e663. https:\/\/doi.org\/10.1212\/NXI.0000000000000663","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"1511_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391\u2013404. https:\/\/doi.org\/10.1016\/S1474-4422(15)00401-9","journal-title":"Lancet Neurol"},{"issue":"9","key":"1511_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"Pt 8","key":"1511_CR15","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/brain\/awh203","volume":"127","author":"J Dalmau","year":"2004","unstructured":"Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127(Pt 8):1831\u20131844. https:\/\/doi.org\/10.1093\/brain\/awh203","journal-title":"Brain"},{"issue":"5","key":"1511_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-018-0363-6","volume":"54","author":"A De la Hoz","year":"2019","unstructured":"De la Hoz A, Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP (2019) Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin\u2019s disease. Bone Marrow Transpl 54(5):749\u2013751. https:\/\/doi.org\/10.1038\/s41409-018-0363-6","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"1511_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J et al (2017) Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, including a Case Series of Encephalitis. Oncologist 22(6):709\u2013718. https:\/\/doi.org\/10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"},{"issue":"12","key":"1511_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","volume":"13","author":"LM Yshii","year":"2017","unstructured":"Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13(12):755\u2013763. https:\/\/doi.org\/10.1038\/nrneurol.2017.144","journal-title":"Nat Rev Neurol"},{"key":"1511_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1742-2094-8-155","volume":"8","author":"CL Pittet","year":"2011","unstructured":"Pittet CL, Newcombe J, Prat A, Arbour N (2011) Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 8:155. https:\/\/doi.org\/10.1186\/1742-2094-8-155","journal-title":"J Neuroinflammation"},{"issue":"8","key":"1511_CR20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","volume":"25","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE et al (2019) A case report of clonal EBV-like memory CD4\u2009+\u2009T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 25(8):1243\u20131250. https:\/\/doi.org\/10.1038\/s41591-019-0523-2","journal-title":"Nat Med"},{"issue":"5","key":"1511_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jama.2020.17308","volume":"325","author":"PD Reid","year":"2021","unstructured":"Reid PD, Cifu AS, Bass AR (2021) Management of immunotherapy-related toxicities in patients treated with Immune checkpoint inhibitor therapy. JAMA 325(5):482\u2013483. https:\/\/doi.org\/10.1001\/jama.2020.17308","journal-title":"JAMA"},{"key":"1511_CR22","doi-asserted-by":"publisher","first-page":"175628561772234","DOI":"10.1177\/1756285617722347","volume":"11","author":"YW Shin","year":"2017","unstructured":"Shin YW, Lee ST, Park KI, Jung KH, Jung KY, Lee SK, Chu K (2017) Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord 11:1756285617722347. https:\/\/doi.org\/10.1177\/1756285617722347","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1511_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangu\u00e9 T, Glaser C, Iizuka T et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157\u2013165. https:\/\/doi.org\/10.1016\/S1474-4422(12)70310-1","journal-title":"Lancet Neurol"},{"issue":"18","key":"1511_CR24","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","volume":"86","author":"WJ Lee","year":"2016","unstructured":"Lee WJ, Lee ST, Byun JI, Sunwoo JS, Kim TJ, Lim JA et al (2016) Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology 86(18):1683\u20131691. https:\/\/doi.org\/10.1212\/WNL.0000000000002635","journal-title":"Neurology"},{"issue":"5","key":"1511_CR25","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1172\/JCI117519","volume":"94","author":"RR Lobb","year":"1994","unstructured":"Lobb RR, Hemler ME (1994) The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 94(5):1722\u20131728. https:\/\/doi.org\/10.1172\/JCI117519","journal-title":"J Clin Invest"},{"issue":"2","key":"1511_CR26","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1212\/NXI.0000000000000439","volume":"5","author":"AF Hottinger","year":"2018","unstructured":"Hottinger AF, de Micheli R, Guido V, Karampera A, Hagmann P, Du Pasquier R (2018) Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. Neurol Neuroimmunol Neuroinflamm 5(2):e439. https:\/\/doi.org\/10.1212\/NXI.0000000000000439","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1511_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejca.2020.12.014","volume":"145","author":"S Basin","year":"2021","unstructured":"Basin S, Perrin J, Michot JM, Lambotte O, Cauquil C (2021) Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy. Eur J Cancer 145:230\u2013233. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.014","journal-title":"Eur J Cancer"},{"issue":"1","key":"1511_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","volume":"145","author":"K Sato","year":"2019","unstructured":"Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug Event Report database. J Neurooncol 145(1):1\u20139. https:\/\/doi.org\/10.1007\/s11060-019-03273-1","journal-title":"J Neurooncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01511-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:39:56Z","timestamp":1746193196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01511-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01511-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}